Vitamin D3 for Life

Live Enlightened

Physiology

Infant Vitamin D Sources and Status: Full Evidence Review

Previous related pageInfant Vitamin D Sources and Status: Study SummaryNext related pageInfant Vitamin D Sources and Status: Study Summary
Study at a glance

What was studied?

Researchers compared vitamin D supplementation strategies in infants. Some infants were born at term, at the usual stage of pregnancy. Others were born early and received specialist care. One trial compared a supplement given to breastfeeding mothers with a supplement given directly to infants. Most studies measured 25-hydroxyvitamin D, a blood substance used to assess vitamin D status.

What did the studies find?

Higher infant doses generally raised the blood measurement. In term infants, this did not consistently produce an added bone benefit. A tested high-maternal-dose strategy produced similar infant blood status to direct infant supplementation among pairs who continued breastfeeding. An intermediate maternal-dose arm was stopped because of infant deficiency.

What does this mean?

A supplement can change a blood result without proving better health. Starting status, feeding circumstances and other nutritional sources matter. A supplement dose is not always the total amount received.

What are the limits?

Some trials were small or lost many participants during follow-up. The studies of infants born early were short. Milk vitamin D was not measured in the maternal-route trial. These studies do not establish one best intake or blood target for every infant. Research doses are not instructions for infant care.

Read the full article below ↓

An infant’s vitamin D status reflects more than the amount printed on a supplement bottle. Starting status, the route of supplementation, other nutritional sources and the stage of development all affect how a study should be interpreted. Trials can show how a particular strategy changes a blood measurement without establishing the best intake for every infant. This review compares six independent trial groups in term and preterm infants, including a maternal supplementation study during breastfeeding. For a shorter account, read Infant Vitamin D Sources and Status: Study Summary.

What the blood measurement can tell us

The main measurement in these studies is 25-hydroxyvitamin D, written as 25(OH)D. It is a circulating vitamin D metabolite used to assess vitamin D status. It is not the same substance as vitamin D3 in the supplement, or the active hormone, 1,25-dihydroxyvitamin D. A measured increase in 25(OH)D therefore answers a specific question about circulating status. It does not directly measure how much mineral entered bone, how a tissue responded, or whether an infant had fewer illnesses. The distinction between the two blood markers is explained in Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D. The separate conversion steps are introduced in Vitamin D Activation.

This distinction also affects the meaning of “needs”. A trial comparing two supplement amounts can estimate their effects in the infants studied. It cannot, by itself, identify the minimum individual requirement or establish that the higher concentration is a better clinical target. A convincing intake recommendation would need to consider relevant benefits, harms, total intake and the population to which it will be applied. The studies discussed here do not provide one universal answer to those questions. This is the interpretive problem addressed by Why a Vitamin D Deficiency Threshold Is Not the Same as a Functional Target.

Research doses below describe the experiments. In particular, a maternal dose during lactation and an infant dose are different exposures, and specialist preterm care cannot be transferred directly to a healthy term infant at home. IU means international units, the unit used for the supplement amounts in these reports.

For current UK guidance, see NHS Vitamins for children. Infants born early need advice from their neonatal team.

Healthy term infants: status changes are reproducible, but context matters

Gallo and colleagues enrolled 132 healthy, breastfed term infants in Montreal at about one month of age. They compared daily vitamin D3 supplements of 400, 800, 1,200 and 1,600 IU. Approximately 74% completed the 11-month intervention. The different amounts produced different patterns of 25(OH)D attainment, showing that circulating status responded to the assigned supplement. The experiment did not detect a corresponding advantage in growth or bone mineral accrual with the higher amounts (Gallo et al., 2013).

At three months, mean 25(OH)D was 78 nmol/L (95% confidence interval 71 to 84) in the 400-IU group and 134 nmol/L (118 to 150) in the 1,200-IU group. Concentrations peaked at about three months and then declined from three to 12 months across the groups, despite increasing dietary vitamin D intake (Gallo et al., 2013). This describes the observed time course. It does not, by itself, establish why concentrations declined or prove that infants needed an increasing supplement dose.

The highest-dose arm was stopped after high results from an immunoassay, a laboratory method that uses antibody-based detection. Infants in that arm were switched to 400 IU. Later mass-spectrometry measurements gave lower values, and additional safety investigations were normal. This episode is important for interpreting measurements and monitoring. It should not be rewritten as proof that the infants had toxic injury, nor as proof that the original high-dose strategy was universally safe. The stopped arm also ceased to be an unchanged long-term comparison. The broader distinction between a high laboratory value and calcium-related toxicity is developed in Vitamin D Toxicity and Hypercalcaemia: Mechanisms, Risk and Clinical Interpretation: Evidence Synthesis.

Many participating families were already engaged with supplementation, and the study was not a representative sample of every infant feeding setting. Its findings establish a dose: status relationship under its study conditions. They do not establish that an unsupplemented infant with severe deficiency would follow the same course. Attrition and the modest sample also limit the conclusions available from secondary growth and mineral outcomes.

The larger Finnish Vitamin D Intervention in Infants trial, commonly called VIDI, compared 400 with 1,200 IU of vitamin D3 daily from two weeks to 24 months. Its analysis included 975 infants, and 823 completed follow-up. At birth, 95.7% were already classified as vitamin D sufficient. The higher dose increased measured status, but did not produce additional tibial bone benefit or reduce the overall rate of parent-reported infection (Rosendahl et al., 2018).

VIDI therefore supplies an important comparison: raising a measurement above the level achieved by the lower-dose strategy did not automatically improve the outcomes measured in this largely sufficient population. That is a stronger conclusion than merely observing an association between a blood result and health. It remains narrower than claiming that vitamin D has no role in infant health, or that infants starting with much lower status cannot benefit from correction.

Low status at birth is a different starting point

A later Montreal trial selected term infants whose 25(OH)D at birth was below 50 nmol/L, a blood concentration unit. Ninety-eight infants were randomised at about one month to 400 or 1,000 IU daily. A further 41 infants with sufficient status at birth formed a nonrandomised reference group. Visits at one, three, six and 12 months allowed investigators to examine status over the first year rather than infer a trajectory from a single sample (Gharibeh et al., 2023).

The higher-dose group achieved higher 25(OH)D, but the bone analysis did not demonstrate an added mineral advantage. This extends the comparison beyond VIDI’s largely sufficient starting population. However, the birth-selection threshold does not mean every participant remained deficient at randomisation, and the sample does not represent all degrees of severe deficiency. Birth status, intervention-entry status and subsequent status need to remain separate time points.

The 41 reference infants also need separate interpretation. They were not randomly assigned to have sufficient status at birth. Comparing them with the two intervention groups does not have the same protection against confounding as the randomised 400-versus-1,000 IU comparison. Differences in feeding and other circumstances may contribute to differences between a reference group and the randomised participants.

The trial’s body-composition report found modestly higher absolute lean mass with 1,000 rather than 400 IU at 12 months, but not at three months. Percentage lean mass, a length-adjusted lean-mass index and fat outcomes did not show a corresponding advantage. These are findings from the same trial, not an independent replication (Razaghi et al., 2022). Together, the reports show why the status result should not be reduced either to “higher is better” or to “nothing else changed”. The separate outcomes review examines those distinctions in more detail.

During breastfeeding: the delivery route changes the question

Hollis and colleagues compared maternal and direct infant supplementation in mother: infant pairs entering a trial four to six weeks after birth. The study included maternal daily doses of 400, 2,400 or 6,400 IU. Infants received 400 IU directly in the maternal 400-IU arm; infants in the higher maternal-dose arms did not receive that active infant supplement. The intermediate maternal-dose arm was stopped because of infant deficiency (Hollis et al., 2015).

Among the continuing breastfeeding pairs, investigators reported similar infant vitamin D status with the tested high-maternal-dose strategy and the direct-infant strategy. This is evidence that a maternal route can influence infant status under specified research conditions. It is not a comparison of identical doses delivered to the same person. It also does not establish that all maternal supplementation strategies can replace direct infant supplementation.

Continuation of breastfeeding substantially narrowed the observed population. Of 334 pairs in the final two arms, 148 remained breastfeeding at four months and 95 at seven months. The later comparison therefore describes a selected group of continuing pairs. It cannot be assumed to represent everyone initially enrolled, every feeding transition, or families who would find the regimen difficult to maintain.

Milk vitamin D was not measured in this trial. The infant blood results do not justify adding an invented numerical account of milk vitamin D content or declaring a universal breast-milk adequacy threshold. The full principal paper supports a cautious qualitative comparison of infant status. Its unavailable supplementary detail is not used here to assert precise clinical equivalence, subgroup effects or comprehensive safety. A 2019 correction identified swapped labels in panels B and C of Figure 2; the report should be read with that correction.

Prematurity: the supplement is only one part of nutritional exposure

Preterm studies answer a distinct question because the infants receive care in a neonatal unit, with additional feeding and mineral support. The amount assigned as a supplement is not necessarily the total vitamin D received. Interpretation requires knowing whether milk, fortifier, formula or other nutritional delivery contributed additional vitamin D. The mineral context is introduced in Vitamin D and Calcium and Vitamin D and Phosphate Regulation. Those general pathways do not replace the actual feeding and biochemical measurements in a preterm trial. Simply comparing the number on a supplement dose across different trials can conceal those differences.

A 2025 Chiang Mai trial randomised 38 preterm or very-low-birthweight infants to supplemental vitamin D3 at 400 or 800 IU daily. All 38 reached the six-week chronological-age assessment. That assessment was at six weeks of age, after approximately four to five weeks of exposure, not after six complete weeks of treatment. At that point, mean 25(OH)D was 47.3 ng/mL in the 800-IU group and 32.0 ng/mL in the 400-IU group (Rueang-Amnat et al., 2025).

Both groups received the unit’s feeding and mineral care. The assigned study supplement replaced the routine 600-IU hospital supplement; it was not added on top of it. Other nutritional sources still mattered. The result shows a short-term status difference between the tested strategies, not a universal target of 47.3 ng/mL. No added calcium, phosphate or alkaline-phosphatase benefit was detected, and the study did not test improvement in bone imaging or clinical fractures.

The trial was small and conducted in one centre. Clinical staff knew the allocation, although laboratory staff were blinded. Sixteen of 19 infants in the 800-IU group were male, compared with seven of 19 in the 400-IU group, and feeding exposure differed. Randomisation does not guarantee that all relevant characteristics will be balanced in a sample this small. These limitations constrain the precision and transferability of the result.

An independent Nebraska trial provides a narrower supporting observation. Thirty-two infants born at 24 to 32 weeks were assigned 400 or 800 IU of vitamin D3 in addition to other nutritional sources. At four weeks, median status was 84.6 versus 105.3 nmol/L, respectively, with a reported P value of .048 (Anderson-Berry et al., 2017). This supports a short-term dose: status difference in another preterm setting. Internal disagreements between later narrative values, tables and raw data prevent using its disputed later numbers or bone findings as further confirmation.

What the six trials establish together

Across the term-infant comparisons, different supplement strategies changed 25(OH)D. The low-birth-status trial adds a population that differs from the largely sufficient Finnish cohort. The lactation trial tests who receives the supplement, while the two preterm trials add the importance of specialist nutritional care and short follow-up. These are complementary questions; their results should not be pooled as though they were six versions of an identical experiment. Treatment of established nutritional bone disease is a different question, examined in Calcium Availability and Vitamin D Response in Nutritional Rickets: Full Study. That treatment evidence cannot supply a missing optimum intake for healthy infants.

The evidence supports three practical interpretive distinctions. First, the assigned supplement and total nutritional exposure are not interchangeable. Second, a measurement at birth, at treatment entry and later in infancy describes different stages. Third, a higher blood concentration and a better health outcome require separate evidence. These distinctions explain why the studies can be useful even though they do not identify one optimum intake for all infants.

There are also clear limits to this review. It is a selected comparison of assessed trials, not an exhaustive systematic review or a feeding guideline. It does not quantify milk vitamin D, skin production, every formula’s composition or an individual infant’s physiological requirement. Its contribution is to show what the studies actually tested, how infant status responded, and why those responses must be interpreted alongside measured benefits and limitations.

Sources and access

The principal reports and claim-relevant material were assessed. The Hollis and Razaghi supplements were unavailable; their use is limited to the qualitative main-report findings described above. Disputed Nebraska bone and later status claims are excluded. Companion reports from one trial are counted once. Publication titles below identify the sources; a title’s wording is not itself a recommendation or a guarantee of clinical benefit.

Effect of Different Dosages of Oral Vitamin D Supplementation on Vitamin D Status in Healthy, Breastfed Infants: A Randomized Trial. Gallo S et al. JAMA. 2013;309:1785 to 1792. DOI: 10.1001/jama.2013.3404.

Effect of Higher vs Standard Dosage of Vitamin D3 Supplementation on Bone Strength and Infection in Healthy Infants: A Randomized Clinical Trial. Rosendahl J et al. JAMA Pediatrics. 2018;172:646 to 654. DOI: 10.1001/jamapediatrics.2018.0602.

Maternal Versus Infant Vitamin D Supplementation During Lactation: A Randomized Controlled Trial. Hollis BW et al. Pediatrics. 2015;136:625 to 634. DOI: 10.1542/peds.2015-1669. Principal report assessed from an institutional full-text copy.

Maternal Versus Infant Vitamin D Supplementation During Lactation: A Randomized Controlled Trial. Correction. Pediatrics. 2019;144:e20191063. Figure 2B/C labels corrected; not a separate trial.

Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Gharibeh N et al. JAMA Pediatrics. 2023;177:353 to 362. DOI: 10.1001/jamapediatrics.2022.5837.

Correction of neonatal vitamin D status using 1000 IU vitamin D/d increased lean body mass by 12 months of age compared with 400 IU/d: a randomized controlled trial. Razaghi M et al. American Journal of Clinical Nutrition. 2022;115:1612 to 1625. Same trial as Gharibeh; the title refers to correcting status, not an erratum.

Randomized trial of two doses of vitamin D3 in preterm infants <32 weeks: Dose impact on achieving desired serum 25(OH)D3 in a NICU population. Anderson-Berry A et al. PLoS ONE. 2017;12:e0185950. DOI: 10.1371/journal.pone.0185950.

Improving Vitamin D Status in Preterm Newborns: A Randomized Trial of 800 vs. 400 IU/Day. Rueang-Amnat N et al. Nutrients. 2025;17:1888. DOI: 10.3390/nu17111888.

Related reading

Library

Diverse Effects of Combinations of Maternal-Neonatal VDR Polymorphisms and 25-Hydroxyvitamin D Concentrations on Neonatal Birth Anthropometry: Functional Phenocopy Variability Dependence, Highlights the Need for Targeted Maternal 25-Hydroxyvitamin D Cut-Offs during Pregnancy

The aim of this study was to evaluate the combined effect of maternal and neonatal VDR polymorphisms (ApaI, TaqI, BsmI, FokI, Tru9I) and different maternal and neonatal 25(OH)D cut-offs on neonatal birth anthropometry.

Original paper ↗Read more →

Original sources

Source

Vitamins for children

For current UK guidance, see NHS Vitamins for children.

Publication details

For current UK guidance, see NHS Vitamins for children. Infants born early need advice from their neonatal team.

Read more →
Source

Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial

Published in Gharibeh N et al. JAMA Pediatrics (2023).

Publication details

Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Gharibeh N et al. JAMA Pediatrics. 2023;177:353 to 362. DOI: 10.1001/jamapediatrics.2022.5837.

Read more →
Source

Correction of neonatal vitamin D status using 1000 IU vitamin D/d increased lean body mass by 12 months of age compared with 400 IU/d: a randomized controlled trial

Published in Razaghi M et al. American Journal of Clinical Nutrition (2022).

Publication details

Correction of neonatal vitamin D status using 1000 IU vitamin D/d increased lean body mass by 12 months of age compared with 400 IU/d: a randomized controlled trial. Razaghi M et al. American Journal of Clinical Nutrition. 2022;115:1612 to 1625. Same trial as Gharibeh; the title refers to correcting status, not an erratum.

Read more →